Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.

Schellenbacher C, Huber B, Skoll M, Shafti-Keramat S, Roden RBS, Kirnbauer R.

Vaccine. 2019 Jun 12;37(27):3529-3534. doi: 10.1016/j.vaccine.2019.05.011. Epub 2019 May 27.

PMID:
31147274
2.

High-risk Mucosal Human Papillomavirus Infection in Squamous Cell Carcinoma and Bowen's Disease of the Hand.

Dorfer S, Kancz S, Birner P, Strasser K, Kirnbauer R, Petzelbauer P, Radakovic S, Harpain L, Pehamberger H, Thalhammer F, Handisurya A.

Acta Derm Venereol. 2019 Apr 1;99(4):462-463. doi: 10.2340/00015555-3115. No abstract available.

3.

The Kühtai data set: 25 years of lysimetric, snow pillow, and meteorological measurements.

Krajči P, Kirnbauer R, Parajka J, Schöber J, Blöschl G.

Water Resour Res. 2017 Jun;53(6):5158-5165. doi: 10.1002/2017WR020445. Epub 2017 Jun 13.

4.

Type-specific L1 virus-like particle-mediated protection of horses from experimental bovine papillomavirus 1-induced pseudo-sarcoid formation is long-lasting.

Harnacker J, Hainisch EK, Shafti-Keramat S, Kirnbauer R, Brandt S.

J Gen Virol. 2017 Jun;98(6):1329-1333. doi: 10.1099/jgv.0.000791. Epub 2017 Jun 21.

PMID:
28635592
5.

Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in horse.

Hainisch EK, Abel-Reichwald H, Shafti-Keramat S, Pratscher B, Corteggio A, Borzacchiello G, Wetzig M, Jindra C, Tichy A, Kirnbauer R, Brandt S.

J Gen Virol. 2017 Feb;98(2):230-241. doi: 10.1099/jgv.0.000673.

PMID:
28284277
6.

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).

Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R.

PLoS One. 2017 Jan 5;12(1):e0169533. doi: 10.1371/journal.pone.0169533. eCollection 2017.

7.

Developments in L2-based human papillomavirus (HPV) vaccines.

Schellenbacher C, Roden RBS, Kirnbauer R.

Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23. Review.

8.

Setback distances between small biological wastewater treatment systems and drinking water wells against virus contamination in alluvial aquifers.

Blaschke AP, Derx J, Zessner M, Kirnbauer R, Kavka G, Strelec H, Farnleitner AH, Pang L.

Sci Total Environ. 2016 Dec 15;573:278-289. doi: 10.1016/j.scitotenv.2016.08.075. Epub 2016 Aug 26.

9.

Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.

Handisurya A, Schellenbacher C, Haitel A, Senger T, Kirnbauer R.

Br J Cancer. 2016 Feb 16;114(4):409-16. doi: 10.1038/bjc.2015.462. Epub 2016 Feb 11.

10.

Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition.

Handisurya A, Lázár S, Papay P, Primas C, Haitel A, Horvat R, Tanew A, Vogelsang H, Kirnbauer R.

Acta Derm Venereol. 2016 May;96(4):494-8. doi: 10.2340/00015555-2298.

11.

Correction: Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Jindra C, Huber B, Shafti-Keramat S, Wolschek M, Ferko B, Muster T, Brandt S, Kirnbauer R.

PLoS One. 2015 Nov 12;10(11):e0143269. doi: 10.1371/journal.pone.0143269. eCollection 2015. No abstract available.

12.

Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors.

Schellenbacher C, Shafti-Keramat S, Huber B, Fink D, Brandt S, Kirnbauer R.

Virology. 2015 Dec;486:284-90. doi: 10.1016/j.virol.2015.08.016. Epub 2015 Oct 28.

13.

Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Jindra C, Huber B, Shafti-Keramat S, Wolschek M, Ferko B, Muster T, Brandt S, Kirnbauer R.

PLoS One. 2015 Sep 18;10(9):e0138722. doi: 10.1371/journal.pone.0138722. eCollection 2015. Erratum in: PLoS One. 2015;10(11):e0143269.

14.

A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.

Huber B, Schellenbacher C, Jindra C, Fink D, Shafti-Keramat S, Kirnbauer R.

PLoS One. 2015 Mar 19;10(3):e0120152. doi: 10.1371/journal.pone.0120152. eCollection 2015.

15.

Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study.

Namujju PB, Pajunen E, Simen-Kapeu A, Hedman L, Merikukka M, Surcel HM, Kirnbauer R, Apter D, Paavonen J, Hedman K, Lehtinen M.

BMC Res Notes. 2014 Jul 11;7:445. doi: 10.1186/1756-0500-7-445.

16.

Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.

Kwak K, Jiang R, Wang JW, Jagu S, Kirnbauer R, Roden RB.

PLoS One. 2014 May 9;9(5):e97232. doi: 10.1371/journal.pone.0097232. eCollection 2014.

17.

Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.

Wang JW, Jagu S, Kwak K, Wang C, Peng S, Kirnbauer R, Roden RB.

Virology. 2014 Jan 20;449:304-16. doi: 10.1016/j.virol.2013.10.038. Epub 2013 Dec 20.

18.

Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.

Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RBS, Kirnbauer R.

J Invest Dermatol. 2013 Dec;133(12):2706-2713. doi: 10.1038/jid.2013.253. Epub 2013 May 10.

19.

Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses.

Hainisch EK, Brandt S, Shafti-Keramat S, Van den Hoven R, Kirnbauer R.

Equine Vet J. 2012 Jan;44(1):107-11. doi: 10.1111/j.2042-3306.2011.00390.x. Epub 2011 Sep 6.

20.

Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation.

Hartl B, Hainisch EK, Shafti-Keramat S, Kirnbauer R, Corteggio A, Borzacchiello G, Tober R, Kainzbauer C, Pratscher B, Brandt S.

J Gen Virol. 2011 Oct;92(Pt 10):2437-2445. doi: 10.1099/vir.0.033670-0. Epub 2011 Jun 29.

21.

Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence.

Namujju PB, Hedman L, Hedman K, Banura C, Mbidde EK, Kizito D, Byaruhanga RN, Muwanga M, Kirnbauer R, Surcel HM, Lehtinen M.

BMC Res Notes. 2011 Jun 6;4:170. doi: 10.1186/1756-0500-4-170.

22.

Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33.

Merikukka M, Kaasila M, Namujju PB, Palmroth J, Kirnbauer R, Paavonen J, Surcel HM, Lehtinen M.

Int J Cancer. 2011 Mar 1;128(5):1114-9. doi: 10.1002/ijc.25675. Epub 2010 Nov 28.

23.

A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.

Handisurya A, Schellenbacher C, Reininger B, Koszik F, Vyhnanek P, Heitger A, Kirnbauer R, Förster-Waldl E.

Vaccine. 2010 Jul 5;28(30):4837-41. doi: 10.1016/j.vaccine.2010.04.057. Epub 2010 May 14.

24.

Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women.

Namujju PB, Surcel HM, Kirnbauer R, Kaasila M, Banura C, Byaruhanga R, Muwanga M, Mbidde EK, Koskela P, Lehtinen M.

Scand J Infect Dis. 2010 Jul;42(6-7):522-6. doi: 10.3109/00365540903582426.

PMID:
20180681
25.

[HPV infections of the oral and genital mucosa. Possibilities for primary prevention].

Kirnbauer R, Schellenbacher C, Shafti-Keramat S, Handisurya A.

Hautarzt. 2009 Nov;60(11):878-80. doi: 10.1007/s00105-009-1803-4. German.

PMID:
19862489
26.

Hydrological modeling in alpine catchments: sensing the critical parameters towards an efficient model calibration.

Achleitner S, Rinderer M, Kirnbauer R.

Water Sci Technol. 2009;60(6):1507-14. doi: 10.2166/wst.2009.488.

PMID:
19759453
27.

Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes.

Shafti-Keramat S, Schellenbacher C, Handisurya A, Christensen N, Reininger B, Brandt S, Kirnbauer R.

Virology. 2009 Oct 10;393(1):1-6. doi: 10.1016/j.virol.2009.07.036. Epub 2009 Sep 3.

28.

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

Schellenbacher C, Roden R, Kirnbauer R.

J Virol. 2009 Oct;83(19):10085-95. doi: 10.1128/JVI.01088-09. Epub 2009 Jul 29.

29.

Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.

Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R.

Sex Transm Infect. 2009 Aug;85(4):261-3. doi: 10.1136/sti.2008.034959.

30.

Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women.

Kaasila M, Koskela P, Kirnbauer R, Pukkala E, Surcel HM, Lehtinen M.

Int J Cancer. 2009 Nov 1;125(9):2166-72. doi: 10.1002/ijc.24539.

31.

Diseases caused by human papillomaviruses (HPV).

Handisurya A, Schellenbacher C, Kirnbauer R.

J Dtsch Dermatol Ges. 2009 May;7(5):453-66; quiz 466, 467. doi: 10.1111/j.1610-0387.2009.06988.x. Epub 2009 Mar 6. Review. English, German.

PMID:
19302229
32.

Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2.

Lin Z, Yemelyanova AV, Gambhira R, Jagu S, Meyers C, Kirnbauer R, Ronnett BM, Gravitt PE, Roden RB.

Am J Pathol. 2009 Jan;174(1):136-43. doi: 10.2353/ajpath.2009.080588. Epub 2008 Dec 18.

33.

Serological relationship between cutaneous human papillomavirus types 5, 8 and 92.

Handisurya A, Gambhira R, Schellenbacher C, Shafti-Keramat S, Forslund O, Favre M, Kirnbauer R.

J Gen Virol. 2009 Jan;90(Pt 1):136-43. doi: 10.1099/vir.0.006189-0.

34.

[Anal HPV infections].

Aigner F, Conrad F, Widschwendter A, Zangerle R, Zelger B, Haidenberger A, Roka S, Heim K, Höpfl R, Klimpfinger M, Rigler YM, Bonatti H, Pfeifer J, Maier A, Kirnbauer R, Salat A.

Wien Klin Wochenschr. 2008;120(19-20):631-41. doi: 10.1007/s00508-008-1059-5. German. No abstract available.

PMID:
19083168
35.

Peripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equines.

Brandt S, Haralambus R, Schoster A, Kirnbauer R, Stanek C.

J Gen Virol. 2008 Jun;89(Pt 6):1390-1395. doi: 10.1099/vir.0.83568-0.

PMID:
18474554
36.

A subset of equine sarcoids harbours BPV-1 DNA in a complex with L1 major capsid protein.

Brandt S, Haralambus R, Shafti-Keramat S, Steinborn R, Stanek C, Kirnbauer R.

Virology. 2008 Jun 5;375(2):433-41. doi: 10.1016/j.virol.2008.02.014. Epub 2008 Apr 18.

37.

New Chlamydia trachomatis L2 strains identified in a recent outbreak of lymphogranuloma venereum in Vienna, Austria.

Stary G, Meyer T, Bangert C, Kohrgruber N, Gmeinhart B, Kirnbauer R, Jantschitsch C, Rieger A, Stary A, Geusau A.

Sex Transm Dis. 2008 Apr;35(4):377-82. doi: 10.1097/OLQ.0b013e31815d6df8.

PMID:
18209688
38.

Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions.

Andersson K, Waterboer T, Kirnbauer R, Slupetzky K, Iftner T, de Villiers EM, Forslund O, Pawlita M, Dillner J.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):189-95. doi: 10.1158/1055-9965.EPI-07-0405.

39.

Anal human papillomavirus testing with Digene's hybrid capture 2 using two different sampling methods.

Roka F, Roka J, Trost A, Schalk H, Zagler C, Kirnbauer R, Salat A.

Dis Colon Rectum. 2008 Jan;51(1):62-6. Epub 2007 Nov 21.

PMID:
18030530
40.

Cutaneous human papillomavirus 88: remarkable differences in viral load.

Kullander J, Handisurya A, Forslund O, Geusau A, Kirnbauer R, Dillner J.

Int J Cancer. 2008 Jan 15;122(2):477-80.

41.

Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma.

Forslund O, Iftner T, Andersson K, Lindelof B, Hradil E, Nordin P, Stenquist B, Kirnbauer R, Dillner J, de Villiers EM; Viraskin Study Group.

J Infect Dis. 2007 Sep 15;196(6):876-83. Epub 2007 Aug 6.

42.

Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy.

Handisurya A, Rieger A, Bankier A, Koller A, Salat A, Stingl G, Kirnbauer R.

Br J Dermatol. 2007 Oct;157(4):788-94. Epub 2007 Jul 19. Erratum in: Br J Dermatol. 2007 Dec;157(6):1304.

43.

[HPV vaccines. Prophylactic vaccines from virus-like particles].

Kirnbauer R.

Hautarzt. 2007 Jun;58(6):489-92. Review. German.

PMID:
17483914
44.

Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells.

Handisurya A, Gilch S, Winter D, Shafti-Keramat S, Maurer D, Schätzl HM, Kirnbauer R.

FEBS J. 2007 Apr;274(7):1747-58. Epub 2007 Feb 20.

45.

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R.

Vaccine. 2007 Mar 1;25(11):2001-10. Epub 2006 Nov 29.

46.

Identification of a de novo keratin 1 mutation in epidermolytic hyperkeratosis with palmoplantar involvement.

Math A, Frank J, Handisurya A, Poblete-Gutiérrez P, Slupetzky K, Födinger D, Winter D, Stingl G, Kirnbauer R.

Eur J Dermatol. 2006 Sep-Oct;16(5):507-10.

PMID:
17101470
47.

Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice.

Zamora E, Handisurya A, Shafti-Keramat S, Borchelt D, Rudow G, Conant K, Cox C, Troncoso JC, Kirnbauer R.

J Immunol. 2006 Aug 15;177(4):2662-2670.

48.

Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression.

Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Mühlbacher F, Salat A.

Transpl Int. 2004 Aug;17(7):366-9. Epub 2004 Jul 31.

49.

High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "Stripped" biopsies from the same tumors.

Forslund O, Lindelöf B, Hradil E, Nordin P, Stenquist B, Kirnbauer R, Slupetzky K, Dillner J.

J Invest Dermatol. 2004 Aug;123(2):388-94.

50.

230-kDa and 190-kDa proteins in addition to desmoglein 1 as immunological targets in a subset of pemphigus foliaceus with a combined cell-surface and basement membrane zone immune staining pattern.

Karlhofer FM, Hashimoto T, Slupetzky K, Kiss M, Liu Y, Amagai M, Pieczkowski F, Foedinger D, Kirnbauer R, Stingl G.

Exp Dermatol. 2003 Oct;12(5):646-54.

PMID:
14705806

Supplemental Content

Loading ...
Support Center